查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494721

吉米沙星全球市場：按形式、症狀和銷售管道- 預測（2024-2030）

Gemifloxacin Market by Form (Solution, Tablet), Indication (Respiratory Infection, Urinary Tract Infection), Sales Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球吉米沙星市場規模為70559萬美元，2024年達74101萬美元，2030年達到98509萬美元，複合年成長率為4.88%。

吉米沙星是一種屬於Fluoroquinolones家族的抗生素，主要用於治療細菌感染疾病，特別是呼吸道感染疾病，包括慢性支氣管炎和肺炎的急性發作。吉米沙星透過抑制 DNA 複製、轉錄、修復和重組所必需的細菌酶發揮作用，有效阻止細菌生長和擴散。患有呼吸道感染疾病（包括慢性支氣管炎和肺炎）的患者數量不斷增加，大大增加了對有效治療方法（包括吉米沙星）的需求。世界對抗生素抗藥性日益關注，因此需要更有效的治療方法。吉米沙星已顯示出對其他抗生素抗藥性的病原體的功效，因此可能提供一種替代治療策略。擴大吉米沙星配方和應用的研發活動的增加預計將為市場成長創造機會。

主要市場統計
基準年[2023] 70559萬美元
預計年份 [2024] 74101萬美元
預測年份 [2030] 98509萬美元
複合年成長率（%） 4.88%

區域洞察

由於醫療基礎設施的改善以及抗生素核准和使用方面的嚴格規定，用於治療細菌感染疾病（吉米沙星）市場在美洲顯著成長。對抗生素抗藥性的認知也在推動研究，審慎的處方實踐是美洲市場成長的基石。在醫療成本上升、人口成長和對呼吸道疾病認知不斷提高的推動下，亞太地區吉米沙星市場正在快速成長。中國、日本和印度等國家由於人口眾多且獲得醫療服務的機會不斷增加，因此在這一成長中處於領先地位。然而，不同國家有不同的醫療標準和監管環境，這可能會影響市場動態，包括抗生素的供應和核准。在歐洲、中東和非洲，吉米沙星的市場動態受到強力的法律規範的影響，特別是在歐洲，該框架確保抗生素的安全分配和處方。歐洲先進的醫療體系和高昂的醫療費用有助於吉米沙星的穩定需求。中東和非洲市場的擴張主要是由於經濟波動、獲得醫療保健的差異以及一些國家的監管挑戰。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在吉米沙星市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對吉米沙星市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對當前吉米沙星市場地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 廣譜抗菌特性增加了對吉米沙星的需求
      • 醫療基礎設施的支持性改革以增加抗生素的獲取
    • 抑制因素
      • 因安全問題而召回產品
    • 機會
      • 吉米沙星生產技術不斷進步
      • 製藥公司與學術/研究機構之間的合作關係
    • 任務
      • 仿冒品的盛行與製造問題
  • 市場區隔分析
    • 劑型：吉米沙星片劑由於其方便常規門診使用而擴大使用
    • 銷售管道：根據醫療保健專業人員的診斷和處方箋，透過醫院藥房擴大吉米沙星的獲取範圍
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 吉米沙星市場：依形式

  • 液體劑
  • 藥片

第7章 吉米沙星市場：依症狀

  • 呼吸道感染
  • 尿道感染

第8章 吉米沙星市場：按銷售管道

  • 醫院藥房
  • 網路商店
  • 零售藥房

第9章 美洲吉米沙星市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太吉米沙星市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲吉米沙星市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭場景分析
    • Sun Pharma 與太郎製藥簽署收購協議
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5D693B46C82C

[190 Pages Report] The Gemifloxacin Market size was estimated at USD 705.59 million in 2023 and expected to reach USD 741.01 million in 2024, at a CAGR 4.88% to reach USD 985.09 million by 2030.

Gemifloxacin is an antibiotic belonging to the fluoroquinolone class and is primarily prescribed to treat bacterial infections, particularly respiratory infections, including acute bacterial exacerbation of chronic bronchitis and pneumonia. Gemifloxacin works by inhibiting bacterial enzymes that are essential for DNA replication, transcription, repair, and recombination, effectively stopping the bacteria from multiplying and spreading. The rising number of cases involving respiratory tract infections, including chronic bronchitis and pneumonia, significantly contributes to the need for effective treatments, including gemifloxacin. There is a continuous need for more effective treatments due to the growing global concern over antibiotic resistance. Gemifloxacin has shown efficacy against pathogens resistant to other antibiotic options, thus providing an alternative treatment course. The availability of certain side effects and safety concerns hampers the market growth. Rising research & development activities to expand the formulation and application of gemifloxacin are expected to create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 705.59 million
Estimated Year [2024] USD 741.01 million
Forecast Year [2030] USD 985.09 million
CAGR (%) 4.88%

Regional Insights

In the Americas, the market for gemifloxacin, an antibiotic used to treat bacterial infections, is significantly growing due to its well-established healthcare infrastructure and stringent regulations regarding antibiotic approval and usage. Awareness about antibiotic resistance also drives research, and careful prescription practices create a platform for market growth in the Americas. The Asia-Pacific region is witnessing rapid growth in the gemifloxacin market, which is attributed to increasing healthcare expenditures, a rising population, and heightened awareness of respiratory diseases. Countries including China, Japan, and India are leading this growth due to their large populations and increasing access to healthcare services. However, the variation in healthcare standards and regulatory landscapes across different countries can affect market dynamics, including the availability and approval of antibiotics, including gemifloxacin. In the EMEA region, the market dynamics of gemifloxacin are influenced by a strong regulatory framework, especially in Europe, which ensures that antibiotics are safely distributed and prescribed. Europe's advanced healthcare systems and high healthcare spending contribute to a stable demand for Gemifloxacin. In the Middle East and Africa, the market is growing primarily due to economic variability, differing healthcare access, and regulatory challenges in some countries.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Gemifloxacin Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
      • Supportive reforms in healthcare infrastructure enhancing access to antibiotics
    • Market Restraints
      • Product recalls due to safety concerns
    • Market Opportunities
      • Continuous advancements in production technologies of gemifloxacin
      • Partnerships between pharmaceutical companies and academic or research institutions
    • Market Challenges
      • Prevalence of counterfeit products and production issues
  • Market Segmentation Analysis
    • Form: Growing availability of tablet form of gemifloxacin as it is convenient for regular outpatient use
    • Sales Channel: Growing accessibility of gemifloxacin through hospital pharmacies following a diagnosis and prescription from a healthcare professional
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Gemifloxacin Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Gemifloxacin Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Sun Pharma Finalizes Acquisition Agreement with Taro Pharmaceutical

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. have officially declared a completed merger agreement. Under this arrangement, Sun Pharma, which is already the majority shareholder of Taro, purchases all outstanding shares of Taro not currently held by Sun Pharma or its affiliates for USD 43.00 per share in cash. This move consolidates Sun Pharma's holdings and simplifies Taro's ownership structure, strengthening its market position in the pharmaceutical industry. [Published On: 2024-01-17]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Gemifloxacin Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Gemifloxacin Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Aurobindo Pharma Limited, BASF SE, Emcure Pharmaceuticals Ltd., Hanmi Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Orchid Chemicals & Pharmaceuticals Ltd., Pfizer Inc., Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Gemifloxacin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Form
    • Solution
    • Tablet
  • Indication
    • Respiratory Infection
    • Urinary Tract Infection
  • Sales Channel
    • Hospital Pharmacy
    • Online Stores
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
      • 5.1.1.2. Supportive reforms in healthcare infrastructure enhancing access to antibiotics
    • 5.1.2. Restraints
      • 5.1.2.1. Product recalls due to safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in production technologies of gemifloxacin
      • 5.1.3.2. Partnerships between pharmaceutical companies and academic or research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of counterfeit products and production issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Growing availability of tablet form of gemifloxacin as it is convenient for regular outpatient use
    • 5.2.2. Sales Channel: Growing accessibility of gemifloxacin through hospital pharmacies following a diagnosis and prescription from a healthcare professional
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Gemifloxacin Market, by Form

  • 6.1. Introduction
  • 6.2. Solution
  • 6.3. Tablet

7. Gemifloxacin Market, by Indication

  • 7.1. Introduction
  • 7.2. Respiratory Infection
  • 7.3. Urinary Tract Infection

8. Gemifloxacin Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Stores
  • 8.4. Retail Pharmacy

9. Americas Gemifloxacin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gemifloxacin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gemifloxacin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sun Pharma Finalizes Acquisition Agreement with Taro Pharmaceutical
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GEMIFLOXACIN MARKET RESEARCH PROCESS
  • FIGURE 2. GEMIFLOXACIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GEMIFLOXACIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GEMIFLOXACIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SOLUTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SOLUTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GEMIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GEMIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE STORES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. BRAZIL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 42. BRAZIL GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. CANADA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 48. CANADA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. MEXICO GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 54. MEXICO GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 60. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 76. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. CHINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 82. CHINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. INDIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 88. INDIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDONESIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 94. INDONESIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. JAPAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 100. JAPAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 106. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 112. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 118. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 124. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. TAIWAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 130. TAIWAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. THAILAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 136. THAILAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. VIETNAM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 142. VIETNAM GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. DENMARK GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 156. DENMARK GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. EGYPT GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 162. EGYPT GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. FINLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 168. FINLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FRANCE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 174. FRANCE GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. GERMANY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 180. GERMANY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. ISRAEL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 186. ISRAEL GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ITALY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 192. ITALY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 198. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NIGERIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 204. NIGERIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NORWAY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 210. NORWAY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. POLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 216. POLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. QATAR GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 222. QATAR GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. RUSSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 228. RUSSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 234. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SPAIN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 246. SPAIN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SWEDEN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 252. SWEDEN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 258. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. TURKEY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 264. TURKEY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 282. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023